A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Public ClinicalTrials.gov record NCT07205718. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Dose Escalation and Expansion, Phase 1/2 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TAK- 188, an Anti-CCR8 Antibody-Drug- Conjugate, as a Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 may help to remove these Tregs. Removing these Tregs may allow more cancer-fighting cells (CD8+ T cells) to attack the tumor and potentially stop tumors from growing. In this study, researchers want to learn if TAK-188 can help the body's immune system better fight cancer in adults with advanced cancers which have not gotten better with regular treatments. The main aims of this study are to check if TAK-188 is safe in adults with advanced or spreading (metastatic) solid tumors, if participants tolerate the treatment with TAK-188 and to learn if TAK-188 works well in adults with certain advanced cancers after their previous treatments didn't work. Participants may receive TAK-188 for up to 1 year. Their health will be monitored after the treatment has ended for up to another year.
Study identification
- NCT ID
- NCT07205718
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 223 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 18, 2025
- Primary completion
- Dec 25, 2028
- Completion
- Dec 20, 2029
- Last update posted
- Jul 16, 2026
2025 – 2029
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Health-Santa Monica Cancer Care (Cancer Care - Santa Monica) | Santa Monica | California | 90404 | Recruiting |
| Yale School of Medicine - Smilow Cancer Hospital - Center for Thoracic Cancers | New Haven | Connecticut | 06511 | Recruiting |
| Florida Cancer Specialists - Lake Nona | Orlando | Florida | 32827 | Recruiting |
| Johns Hopkins | Baltimore | Maryland | 21231 | Recruiting |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | Recruiting |
| START Midwest | Grand Rapids | Michigan | 49546 | Recruiting |
| Washington University | St Louis | Missouri | 63108 | Recruiting |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106-1716 | Recruiting |
| Providence Cancer Institute, Franz Clinic | Portland | Oregon | 97213-2933 | Recruiting |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111-2497 | Recruiting |
| SCRI Oncology | Nashville | Tennessee | 37203 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030-4000 | Recruiting |
| NEXT Dallas | Irving | Texas | 75039 | Recruiting |
| START San Antonio | San Antonio | Texas | 78229 | Recruiting |
| NEXT Virginia | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07205718, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 16, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07205718 live on ClinicalTrials.gov.